OSE Immunotherapeutics Publishes Letter to Shareholders

Group 1 - OSE Immunotherapeutics has published its inaugural Letter to Shareholders, highlighting key achievements, growth strategy foundations, and future perspectives [1] - The company is focused on developing first-in-class assets in immuno-oncology and immuno-inflammation to meet unmet patient needs [2] - OSE Immunotherapeutics collaborates with leading academic institutions and biopharmaceutical companies to develop transformative medicines for serious diseases [2] Group 2 - The company is headquartered between Nantes and Paris and is listed on Euronext [2] - Additional information about the company's assets can be found on its website [3]